Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia. - Wikidata - wikimedia - TriplyDB

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

http://www.wikidata.org/entity/Q37308807

about

Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections Importance of Drug Pharmacokinetics at the Site of Action Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Optimizing Antibiotic Dosing Strategies for the Treatment of Gram-negative Infections in the Era of Resistance.What about confidence intervals? A word of caution when interpreting PTA simulations.Prescribing Ceftolozane/Tazobactam for Pediatric Patients: Current Status and Future Implications.Managing the oncologic patient with suspected pneumonia in the intensive care unit.Challenges and opportunities in the treatment of ventilator-associated pneumonia.PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease Controversies and advances in the management of ventilator associated pneumonia.Potency of parenteral antimicrobials including ceftolozane/tazobactam against nosocomial respiratory tract pathogens: considerations for empiric and directed therapy.Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam.What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance.Multicenter Evaluation of Ceftazidime-Avibactam and Ceftolozane-Tazobactam Inhibitory Activity against Meropenem-Nonsusceptible Pseudomonas aeruginosa from Blood, Respiratory Tract, and Wounds.Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients

P2860

Q26747429-BB842433-313D-47A1-9EDD-F1D419081ACD Q33648045-4187B2D6-F767-4056-8E26-B5D7730E5ADB Q36083619-C38BAA91-6EC1-4484-BF25-EF4AC0A30282 Q38620812-E1A998DC-A4F0-4876-B9C8-FBF6DE77F898 Q38672016-A08405CE-842B-4679-9C82-A3D9DE098277 Q38871384-6A98E6D1-D7E0-475B-8ACB-29BACF3456F6 Q38934400-DB407773-4A27-462D-AE4C-46B78E042528 Q38940456-CCE1D360-CBCB-4B97-8009-49325775A28F Q38988630-08C75ABC-86EA-47CC-A640-AB0C90D40060 Q39066154-A30236D0-5D1B-482D-84BA-9B9E70F73F22 Q40054170-7270D632-D814-4056-B1FE-8E8D081C1457 Q40330973-E5DB2524-79D0-4FC5-AF4F-58532FDCCEE4 Q40526964-8E869D41-6F9E-4976-A1A1-76D9BFE17D37 Q40550507-FD4ADB2B-E3C3-4DF4-8062-59B23A66BAB0 Q47748447-D0BEFC46-02D1-4CC6-8C56-105EED436CE5 Q47822967-71908D67-9D24-459F-A286-FC2A1865592A Q58701649-EE5EFEBD-B45A-4001-9305-9C5B183BA8E0

P2860

Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.

http://www.wikidata.org/entity/Q37308807

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 10 June 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Ceftolozane/tazobactam pharmac ...... nts with nosocomial pneumonia.

@en

Ceftolozane/tazobactam pharmac ...... nts with nosocomial pneumonia.

@nl

type

label

Ceftolozane/tazobactam pharmac ...... nts with nosocomial pneumonia.

@en

Ceftolozane/tazobactam pharmac ...... nts with nosocomial pneumonia.

@nl

prefLabel

Ceftolozane/tazobactam pharmac ...... nts with nosocomial pneumonia.

@en

Ceftolozane/tazobactam pharmac ...... nts with nosocomial pneumonia.

@nl

P1433

Q37308807-5CBACDAE-FF2E-4190-BE95-7077B5C44F79

P1476

Q37308807-3C41CD3F-4796-4056-A5C8-6DAC90634FE7

P2093

Q37308807-869C1043-BF74-40AC-A8CE-E22089D6436D

Q37308807-870D9A4C-9111-4F2B-A27C-C38ECF37D9C5

Q37308807-B663A42B-250F-4C25-8C9F-3984E8FC39C4

Q37308807-BBEAC841-ED1F-4267-9051-9A2055429A50

P2860

Q37308807-0404FE19-C9C7-495B-850F-CD3D735E6A43

Q37308807-06555FD7-42EA-4AD9-8C2E-6F15AE790B9A

Q37308807-19869C6E-BB5E-4A39-BFBD-471B03621257

Q37308807-1FA04C84-585D-4749-BA8D-CD34287C780A

Q37308807-25BC289B-19AE-42FE-8641-84F33215F164

Q37308807-2968BC56-8C7E-4A73-8742-32BCE113F202

Q37308807-3F9C756E-FF6B-4563-81E2-D8A6C3CFF560

Q37308807-5121DAAC-3CEC-43EA-B317-73D1992D9E96

Q37308807-53D2D1D3-130B-4340-A83C-7F2EF4679375

Q37308807-58F5543B-062F-418C-9D70-7F4C74FFB706

P304

Q37308807-F7C2C67F-1140-4569-8901-D4CD08888458

P31

Q37308807-844F9FCB-AFF1-4118-9491-497321CD29A7

P356

Q37308807-6D2C7A33-8E4A-4EE6-B948-CDC3C948ACBF

P433

Q37308807-B596A661-5652-458C-9EA8-D0EB2B5269E4

P478

Q37308807-C1B89EF8-A89E-4E75-92D9-9201192A551A

P577

Q37308807-44D186AE-85D6-45F5-8845-B477E37803CD

P5875

Q37308807-70A23272-13C9-48B2-B294-5DB722140D86

P698

Q37308807-C619C088-C238-4D07-8974-EC84372283E2

P921

Q37308807-3AB4D006-9B96-4B89-B6B2-CE802A452575

P932

Q37308807-1CD2ADBF-0A10-4395-BB72-A1C6673B7DE6

P356

P1433

The Journal of Clinical Pharmacology

P1476

Ceftolozane/tazobactam pharmac ...... nts with nosocomial pneumonia.

@en

P2093

Alan J Xiao

http://www.w3.org/2001/XMLSchema#string

Benjamin W Miller

http://www.w3.org/2001/XMLSchema#string

David P Nicolau

http://www.w3.org/2001/XMLSchema#string

Jennifer A Huntington

http://www.w3.org/2001/XMLSchema#string

P2860

Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia

The antimicrobial therapy puzzle: could pharmacokinetic-pharmacodynamic relationships be helpful in addressing the issue of appropriate pneumonia treatment in critically ill patients?

Pharmacokinetics of meropenem in patients with intra-abdominal infections.

Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections.

Pulmonary penetration of piperacillin and tazobactam in critically ill patients.

Impact of MIC range for Pseudomonas aeruginosa and Streptococcus pneumoniae on the ceftolozane in vivo pharmacokinetic/pharmacodynamic target.

Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'.

In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice.

Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia

Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections.

P304

56-66

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.566

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

279067252

http://www.w3.org/2001/XMLSchema#string

P698

26096377

http://www.w3.org/2001/XMLSchema#string

P921

P932

5049594

http://www.w3.org/2001/XMLSchema#string